Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 57.4%

Neg 0% Neu 0% Pos 57.4%

Citigroup analyst Yigal Nochomovitz initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Buy rating and announces Price Target of $30.